Chinese researchers have studied the adverse reactions observed when efgartigimod, a new-generation immunosuppressant used, among other indications, in refractory autoimmune myasthenia, is administered:
- their work is based on pharmacovigilance data contained in the American database managed by the FDA (Food and Drug Administration),
- which is freely accessible and reports all types of adverse events linked to efgartigimod,
- over the two years studied (2022-2024), 3,040 incidents were reported, 137 of which were considered to be side-effects directly related to the product,
- the authors highlight the frequency of incidents related to various neurological and infectious complications, as well as problems related to non-compliance with the drug’s administration protocol.
